Immunogenicity of current SARS-CoV-2 vaccine schedules currently used in Canada [ISVaC, study data contributed to the CITF Databank]

<b>Background:</b> Vaccines against SARS-CoV-2 virus were developed very quickly: within a year of the pandemic, nearly 200 million vaccine doses had been distributed around the world. Canada, among other countries, opted to extend the time between doses beyond the vaccine manufacturers recommendations due to the high demand for vaccines. <br>

<b>Aims of the CITF-funded study:</b> This study aimed to compare the immunogenicity of time intervals between doses; a standard 28-42 day vaccine schedule and the 4-month schedule established in Canada. They also aimed to determine the effect of pre-existing COVID-19 immune cross-reactivity and antibody reactivity on immunogenicity of the vaccines, as well as investigate the immune response to vaccines in participants with inflammatory bowel diseases treated with immunosuppressive drugs. <br>

<b>Methods:</b> This cohort study enrolled healthcare workers across British Columbia who followed a 4-month COVID-19 vaccine schedule, including some from the CORSIP study. Participants completed a questionnaire at baseline and provided a blood sample. [1] They were followed up a total of 11 times; at baseline, 7, 14, 28 days, and 6 months after their second vaccine, and 40 days after their third vaccination. Participants who had already been vaccinated when recruited only provided blood 3 months after their first dose.

This study also built on data collected in the CORSIP and BCCHR Tracking COVID-19 for Safer Schools CITF-funded studies. <br>

<b>Contributed dataset contents:</b> The datasets include 187 participants who gave one or more blood samples for SARS-CoV-2 serology between January 2021 and January 2022. Variables include data in the following areas of information: age, sex, SARS-CoV-2 vaccination, and serology (SARS-CoV-2 anti-S and anti-RBD). <br>

[1]: Please contact original study team for questionnaire data.